Title
Maternal folic acid supplements associated with reduced autism risk in the child.

Permalink
https://escholarship.org/uc/item/34t8z32g

Journal
Evidence-based medicine, 18(6)

ISSN
1356-5524

Author
Schmidt, Rebecca J

Publication Date
2013-12-01

DOI
10.1136/eb-2013-101311

Peer reviewed
Maternal folic acid supplements associated with reduced autism risk in the child

Rebecca J Schmidt


Context
Autism spectrum disorder (ASD) prevalence is increasing. Maternal periconceptional folic acid intake was associated with reduced ASD risk in a large, population-based case–control study. Surén and colleagues examined whether maternal folic acid supplements were associated with reduced risk for ASD.

Methods
The Norwegian Mother and Child Cohort Study (MoBa) included 85 176 children at least 3 years old born between 1999 and 2009. Questionnaire information on maternal supplement use was obtained around 18-week gestation.

Findings
The 270 MoBa children diagnosed with ASD included 114 with autistic disorder, 56 with Asperger syndrome and 100 with pervasive developmental disorder, not otherwise specified (PDD–NOS). Of the 61 042 children whose mothers took folic acid from 6 weeks before to 6 weeks after conception, 64 (0.10%) had autistic disorder, compared with 50 (0.21%) of the 24 134 children whose mothers did not adjust OR 0.61, 95% CI 0.41 to 0.90. Associations were not found for Asperger syndrome or PDD–NOS.

Commentary
This study replicates previous findings that folic acid supplements taken by mothers before and during early pregnancy are associated with lower risk for autism in the child. The prospective design had a major advantage over previous case–control studies; reporting of supplement use occurred before outcomes were known. Thus recall bias that can occur when case mothers remember past exposures with different accuracy than control mothers was avoided. Another key difference between this and earlier studies is that Norway does not fortify foods with folic acid; previous studies were conducted in the USA during periods of mandatory fortification of cereal grains. In addition, supplements reportedly contained lower folic acid levels (400 µg) than those in the USA (800 µg). Finally, this study’s critical exposure window overlapped, but differed slightly from that of previous studies. Remarkably, despite differences between studies, the authors reported nearly the exact effect size for periconceptional folic acid supplement intake, showing a nearly 40% reduction in autism risk. Despite the large cohort size and multimode approach for ascertaining cases, this study included a small number of children with ASD. As the authors note, this limited examination of differences by case subtypes, and could have introduced ascertainment bias, likely towards the null. ASD prevalence in MoBa (0.3%) was less than half what they reported for Norway (0.8%), indicating markedly incomplete ascertainment, especially for children with Asperger syndrome and PDD–NOS. In addition, only 50% of cases were clinically assessed; the rest relied on specialist–confirmed Norwegian Patient Registry diagnoses that were less reliable for ASD subtypes. These limitations suggest that the findings for at least the ASD subtypes should be interpreted cautiously. Additionally, the authors excluded children with birth outcomes that could be on the pathway between periconceptional folic acid intake and ASD, which likely biased the association towards the null.

Quantitative information on dietary folate and supplemental folic acid was available for mothers at gestational week 22, but not earlier during the relevant exposure period. Consequently, the authors were unable to examine the impact of dietary intake during this time, and ASD risk at different levels of folic acid to replicate the previously shown inverse dose-trend. Effects of maternal and child genotypes that significantly influence folate metabolism and ASD risk were also not evaluated.

Causality for the link between periconceptional folic acid and 50–70% fewer neural tube defects (NTDs) was established through randomised clinical trials. Observational cohort studies have shown associations with reduced risk for severe language delay, behavioural and peer problems, and childhood hyperactivity, and with improved verbal and verbal–executive function, attention and social competence.

Whether the association with autism is causal and what mechanisms are involved remain to be determined. Nevertheless, the overall consistency across studies, and the known protection against NTDs, and potentially other pregnancy and developmental outcomes, argue strongly for women of childbearing age to follow current recommendations to take folic acid supplements before and during early pregnancy. No known adverse conditions are associated with first trimester maternal folic acid at the recommended levels. The proportion of women who started taking folic acid-containing supplements before pregnancy was low in both the USA (45%) and Norwegian (33%).
studies, despite the majority of women reporting their pregnancy as planned (70% and 80%, respectively). Current recommendations regarding early initiation of folic acid supplementation need to be more effectively delivered to the general public.

Competing interests None.

References